Core Viewpoint - Suzhou Rebio Biotechnology Co., Ltd. has successfully listed on the Hong Kong Stock Exchange, becoming the first listed company from Jiangsu in 2023, raising over HKD 1.8 billion to accelerate clinical development and commercialization of innovative therapies [1] Company Overview - Rebio Biotechnology issued 31.61 million shares at an offering price of HKD 57.97 per share [1] - The company is headquartered in Kunshan and has a fully integrated research platform for small nucleic acid drugs, covering all stages from early research to industrialization [1] - Rebio's product pipeline includes seven self-developed drugs that have entered clinical trials, with four currently in Phase II trials [1] Financial and Investment Highlights - The raised capital will be utilized to enhance the clinical development and commercialization processes of its innovative therapies, providing new treatment options for global patients [1] - The company has received significant support from Kunshan, which invested 4 million yuan in its early stages and has continued to support through multiple rounds of financing [1] Industry Context - With Rebio's listing, Kunshan has a total of 51 listed companies, including 35 listed domestically and 16 listed overseas, positioning it among the top cities in China for similar enterprises [1]
江苏新年“第一股”瑞博生物港交所上市